The PI3K{delta}-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo [CLINICAL AND HUMAN IMMUNOLOGY]

Palazzo, A., Herter, S., Grosmaire, L., Jones, R., Frey, C. R., Limani, F., Bacac, M., Umana, P., Oldham, R. J., Marshall, M. J. E., Cox, K. L., Turaj, A. H., Cragg, M. S., Klein, C., Carter, M. J., Tannheimer, S.
The American Association of Immunologists (AAI)
Published 2018